Prescriber Scope of Practice for General Psychiatry in Illinois

If you’re a psychiatrist or psychiatric nurse practitioner wondering whether you can legally prescribe ADHD medications, benzodiazepines, or buprenorphine through telehealth in 2026, you’re not alone. The regulatory landscape has shifted dramatically over the past few years, and the rules are still evolving.

Here’s what you need to know right now: Yes, psychiatrists can prescribe controlled substances via telehealth through at least December 31, 2026, thanks to federal emergency extensions. But that flexibility comes with important caveats—and significant changes are coming that will affect how you practice.

Let’s cut through the confusion and look at what the law actually says, what’s changing, and how to stay compliant while building a sustainable telepsychiatry practice.

The Current State of Telehealth Prescribing (February 2026)

The DEA and HHS announced their fourth extension of COVID-era telehealth flexibilities on January 2, 2026, allowing providers to continue prescribing Schedule II–V controlled substances via telemedicine without an initial in-person exam through the end of 2026. This means you can evaluate a new patient by video and prescribe stimulants for ADHD, benzodiazepines for anxiety, or other controlled medications—just as you’ve been doing since March 2020.

The catch? This is a temporary extension ‘while permanent rules are finalized.’ The DEA has already announced three proposed rules that will fundamentally reshape telehealth prescribing, likely taking effect sometime in 2026 or early 2027.

What You Can Do Right Now

Under the current extension, you can:

• Evaluate new patients via two-way audio-video and prescribe Schedule II–V controlled substances without any prior in-person visit
• Continue treating established patients via telehealth with no federal restrictions (if they’ve ever had an in-person exam with any provider, the Ryan Haight Act’s in-person requirement is already satisfied)
• Prescribe buprenorphine for opioid use disorder via telehealth, including audio-only consultations in many cases
• Practice across state lines as long as you’re licensed in the state where the patient is located and follow that state’s specific rules

The key requirement: you must conduct a legitimate medical evaluation that meets the standard of care. A quick video chat without proper history-taking, mental status exam, and clinical judgment won’t cut it—and regulators are watching.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Changing: The DEA’s Proposed Permanent Rules

In January 2025, the DEA announced three proposed rules that signal where telehealth prescribing is headed. These aren’t finalized yet, but they give us a clear roadmap:

1. Special Telemedicine Registration for Schedule II Prescribing

The DEA is creating a ‘Special Telemedicine Prescriber Registration’ that would allow certain qualified providers to prescribe controlled substances to new patients via telehealth without any in-person exam.

For Schedule III–V substances, any prescriber could apply for this registration. But here’s what matters for psychiatry: board-certified psychiatrists are explicitly included in the group eligible to obtain special registration for Schedule II prescribing.

What this means practically: once finalized, you could register with the DEA as an advanced telemedicine prescriber and legally prescribe Adderall, Ritalin, or other Schedule II medications to new patients you’ve never met in person—provided you conduct a thorough telehealth evaluation.

This is a major policy shift. It acknowledges that psychiatric medications, including stimulants for ADHD, can be safely managed via telehealth for many patients when prescribed by qualified specialists.

The proposed rule would also require:

• Online telehealth platforms to register with the DEA for the first time
• Implementation of a national Prescription Drug Monitoring Program (PDMP) integrating data across states
• Possible annual reporting requirements for telehealth controlled substance prescriptions

2. Buprenorphine Treatment Expansion

The DEA’s proposed rule on buprenorphine would allow providers to initiate treatment for opioid use disorder via telehealth (including audio-only) and continue for up to 6 months before requiring an in-person evaluation.

This is particularly relevant for psychiatrists who treat addiction. After the 6-month mark, you’d need to see the patient in person or refer them to someone who can before continuing buprenorphine prescriptions.

Combined with the 2023 elimination of the X-waiver requirement, this makes medication-assisted treatment far more accessible. Any DEA-registered psychiatrist can now prescribe buprenorphine without special certification—you just need to complete the one-time 8-hour training on substance use disorders required for all DEA renewals.

3. Continuity of Care in Integrated Systems

The third proposed rule addresses the VA system but establishes an important principle: if a patient has had an in-person exam with any provider within an integrated healthcare system, other providers in that system can prescribe controlled substances via telehealth.

While this specifically affects VA providers, it suggests the DEA recognizes the value of care coordination and isn’t rigidly requiring that you personally see every patient in person before prescribing.

State Laws You Can’t Ignore

Here’s where it gets complicated: federal DEA rules set the floor, but states can impose stricter requirements. Even with federal telehealth flexibility, you must follow the most restrictive applicable rule.

State-by-State Breakdown for Priority Markets

Florida has the most nuanced rules. Florida law prohibits prescribing Schedule II controlled substances via telehealth except for psychiatric treatment, inpatient care, hospice, or nursing homes. The psychiatric exception means you can prescribe stimulants for ADHD via telehealth in Florida—but you need to document that it’s for a psychiatric disorder. Schedule III–V medications (most benzodiazepines, buprenorphine) can be prescribed via telehealth with no special restrictions.

Florida also offers an out-of-state telehealth provider registration, allowing you to treat Florida patients without a full Florida medical license—but you’re still bound by Florida’s prescribing rules.

Texas allows telehealth prescribing of controlled substances under federal law but has a critical limitation: psychiatric nurse practitioners cannot prescribe Schedule II medications except in hospital or hospice settings. This means any Texas patient needing ADHD medications must be seen by a physician, not an NP, even on a telehealth platform.

Texas also prohibits prescribing controlled substances for chronic pain via telemedicine without an in-person visit—not usually relevant to psychiatry, but worth knowing if you treat co-morbid pain conditions.

California is telehealth-friendly with no state-specific restrictions beyond federal law. The main compliance requirement is the CURES PDMP check: you must query California’s prescription monitoring database before prescribing Schedule II–IV controlled substances to a new patient and every four months for ongoing treatment. California also requires 100% e-prescribing for all medications.

New York similarly has no additional telehealth prescribing restrictions, but requires checking the state’s I-STOP Prescription Monitoring Program before every Schedule II, III, or IV controlled substance prescription. New York also mandates e-prescribing for all prescriptions, making it one of the strictest states for prescription compliance.

Pennsylvania has no comprehensive telehealth statute yet, operating under general medical board guidance. Telehealth prescribing is allowed as long as you meet the standard of care. You must check the Pennsylvania PDMP before prescribing opioids or benzodiazepines, and controlled substances must be e-prescribed.

Illinois allows telehealth prescribing with no special state restrictions beyond federal requirements. Illinois requires checking the state PDMP before prescribing opioids and mandates e-prescribing for all controlled substances as of 2023.

The Licensing Trap

Here’s something many providers miss: you must be licensed in the state where the patient is physically located at the time of the telehealth visit. Telehealth legally occurs where the patient is, not where you are.

If you want to practice telepsychiatry in multiple states, you need licenses in each state. The Interstate Medical Licensure Compact (IMLC) has made this somewhat easier—California, Texas, Illinois, and Pennsylvania are all members, streamlining the multi-state licensing process for physicians. New York and Florida are not IMLC members, requiring the full traditional licensing process.

For nurse practitioners, scope of practice varies dramatically by state. New York allows full independent practice for experienced PMHNPs (over 3,600 hours). California is transitioning to independence, with full independent practice available by 2026 for experienced NPs. Texas and Florida require physician supervision for all psychiatric NPs, with Texas imposing the Schedule II prescribing ban mentioned earlier.

The Economics of Telehealth Patient Acquisition

Let’s talk about something that doesn’t get enough attention in regulatory discussions: how you actually acquire patients for your telehealth practice matters just as much as staying compliant.

Many psychiatrists and PMHNPs starting in telehealth assume they can market directly to patients for $30-50 per patient through Google Ads or SEO. That’s not the reality.

The True Cost of DIY Marketing

Acquiring a qualified psychiatric patient through your own marketing efforts typically costs $200-500+ per booked patient when you factor in all the hidden expenses:

• Google Ads for mental health keywords run $15-40+ per click, and most clicks don’t convert to scheduled appointments. Your actual cost per booked patient through PPC realistically runs $200-400+.

• SEO takes 6-12 months of consistent investment before generating meaningful patient flow. Most solo providers don’t have the expertise, budget, or patience for this timeline.

• Directory listings like Psychology Today or Zocdoc charge monthly subscription fees AND you compete with hundreds of other providers on the same page. Zocdoc’s per-booking fees run $35-100+, and when you add the monthly subscription cost, your total patient acquisition expense adds up fast.

• Agency and consultant fees for managing ads, optimizing campaigns, and creating content easily run $2,000-4,000/month for professional services.

• Staff time to handle leads, qualify patients, manage no-shows from cold leads, and follow up on inquiries has a real cost even if it doesn’t show up as a direct expense.

• Failed campaigns and testing mean you’ll spend months (and thousands of dollars) figuring out what messaging works before you see consistent results.

Add it all up, and most providers spend $3,000-5,000+ per month on marketing with uncertain returns, especially in the first 6-12 months.

The Platform Alternative

This is where a telehealth platform’s economics make sense. Instead of gambling $5,000/month on marketing that might generate 10-15 patients (or might generate zero), platforms like Klarity Health use a pay-per-appointment model.

You pay a standard listing fee only when a qualified patient books with you. No upfront marketing spend. No monthly subscriptions. No wasted ad budget on clicks that don’t convert.

The value proposition is straightforward:

• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs for video, EHR, e-prescribing)
• Both insurance and cash-pay patient flow depending on your preference
• You control your schedule—only pay when you actually see patients

Think of it this way: would you rather spend $4,000/month on uncertain marketing while building your practice from scratch, or pay a per-appointment fee only when a patient actually shows up? The platform model removes the risk entirely and gives you guaranteed ROI.

For providers just starting out, scaling an existing practice, or those who simply don’t want to become marketing experts, this model makes far more economic sense than DIY patient acquisition.

Practical Compliance Checklist

Here’s what you need to do right now to prescribe controlled substances via telehealth legally and safely:

Federal Requirements:

• [ ] Maintain active DEA registration in each state where you treat patients
• [ ] Complete the one-time 8-hour MATE Act training on substance use disorders (required for DEA renewal since 2023)
• [ ] Conduct thorough audio-video evaluations for new patients (audio-only only for established patients or specific cases like buprenorphine)
• [ ] Use e-prescribing systems with DEA-required two-factor authentication
• [ ] Document evaluations thoroughly to demonstrate standard of care was met
• [ ] Follow your state’s PDMP requirements (query frequency varies by state)

State-Specific:

• [ ] Obtain medical license in each state where patients are located
• [ ] Register as out-of-state telehealth provider if applicable (Florida offers this option)
• [ ] Check your state’s PDMP before prescribing controlled substances (timing and which schedules vary by state)
• [ ] For PMHNPs: Verify your state’s scope of practice and obtain required physician collaboration agreements if needed
• [ ] Ensure your malpractice insurance covers telehealth practice in all states where you see patients

Clinical Documentation:

• [ ] Document patient location at time of each telehealth visit
• [ ] Obtain informed consent for telehealth services (some states require written consent)
• [ ] For Schedule II prescriptions in Florida: Document psychiatric indication
• [ ] Maintain records showing rationale for controlled substance prescriptions
• [ ] Keep documentation of PDMP queries in patient charts

What Happens When the Extension Expires?

The current federal extension runs through December 31, 2026. Assuming the DEA finalizes its proposed rules by then, here’s what will likely change:

For psychiatrists: You’ll probably need to obtain the special telemedicine registration to continue prescribing Schedule II medications to new patients without in-person exams. The registration process details aren’t finalized, but expect to demonstrate board certification and meet certain practice standards.

For buprenorphine: You’ll be able to initiate treatment via telehealth (including audio-only) but will need to arrange an in-person evaluation within 6 months for ongoing treatment.

For established patients: If a patient has ever had an in-person medical exam with any provider, you can continue prescribing via telehealth with no additional requirements.

The DEA is accepting public comments on these rules, and details could change before finalization. The key message: start preparing now for a more structured regulatory framework.

Common Questions Psychiatrists Ask

Can I prescribe Adderall to a new patient via telehealth in 2026?

Yes, under the current federal extension through December 31, 2026. You need to conduct a proper two-way video evaluation, be licensed and DEA-registered in the patient’s state, and follow that state’s specific telehealth and PDMP requirements. Once the permanent rules take effect, you’ll likely need the special telemedicine registration to continue this practice.

Do I need to see patients in person if I have the DEA’s special telemedicine registration?

Based on the proposed rule, no—the special registration would specifically authorize prescribing Schedule II controlled substances via telehealth without any in-person requirement for new patients, as long as you conduct appropriate evaluations.

Can psychiatric nurse practitioners prescribe controlled substances via telehealth?

It depends entirely on the state. In states like New York and California (for experienced NPs), yes—PMHNPs can prescribe controlled substances including Schedule II medications via telehealth within their scope of practice. In Texas, PMHNPs cannot prescribe Schedule II at all in outpatient settings, telehealth or otherwise. Always check your state’s nurse practice act.

What if a patient travels to another state—can I still prescribe?

Legally, you need to be licensed in the state where the patient is physically located at the time of the telehealth visit. If a patient travels, you’d need licensure in that state to continue prescribing. In practice, for short-term travel, this creates gray areas, but the strict legal answer is that you must be licensed wherever the patient is.

Is audio-only telehealth acceptable for prescribing controlled substances?

Currently, the DEA’s proposed buprenorphine rule explicitly allows audio-only for opioid use disorder treatment. For other controlled substances, best practice is two-way video for new patients. Audio-only might be acceptable for established patients in follow-up visits, but video is strongly recommended to meet the standard of care and federal telemedicine requirements.

The Bottom Line for Your Practice

Telehealth prescribing of controlled substances is here to stay, but it’s moving from emergency flexibility to permanent, structured regulation. The new framework will likely benefit board-certified psychiatrists specifically, recognizing your specialized training in managing psychiatric medications including stimulants.

The key to thriving in this environment is threefold:

1. Stay compliant with both federal and state requirements (the most restrictive rule always applies)
2. Maintain thorough documentation showing you’re meeting standards of care
3. Choose patient acquisition strategies that make economic sense—whether that’s investing in long-term SEO and marketing or joining a platform that handles patient flow for you

For most psychiatrists and PMHNPs, especially those building or scaling a practice, the platform model offers the lowest-risk path to sustainable telepsychiatry income. You avoid the marketing gamble, get consistent patient flow, and can focus on what you do best: providing excellent psychiatric care.

If you’re interested in exploring how Klarity Health’s provider network works—where you only pay when qualified patients book with you, with no upfront marketing costs—you can learn more about joining our platform. We handle patient acquisition, credentialing, telehealth infrastructure, and compliance support, letting you focus on treating patients.

The telehealth landscape is complex, but the opportunity is enormous. With the right compliance knowledge and the right patient acquisition strategy, you can build a thriving telepsychiatry practice that serves patients across multiple states while maintaining full regulatory compliance.

Citations and Sources

1. U.S. Department of Health & Human Services. (January 2, 2026). ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release. Retrieved from https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. (January 16, 2025). ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Vital Care.’ Press Release. Retrieved from https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Akerman LLP. (March 2023). ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth.’ Legal Bulletin. Retrieved from https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

4. Texas Medical Board. (Updated 2024). ‘Prescriptive Authority and Delegation FAQs.’ Retrieved from https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

5. Substance Abuse and Mental Health Services Administration. (Updated 2023). ‘Elimination of the DATA Waiver (X-Waiver) Requirement.’ Retrieved from https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act

Note: This content is for informational purposes only and does not constitute legal or medical advice. Regulations change frequently—always verify current requirements with your state medical board, DEA, and legal counsel before implementing telehealth prescribing protocols.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices